PMID- 15016610
OWN - NLM
STAT- MEDLINE
DCOM- 20040806
LR  - 20221207
IS  - 1462-2416 (Print)
IS  - 1462-2416 (Linking)
VI  - 5
IP  - 2
DP  - 2004 Mar
TI  - Association of genetic variations in HLA-B region with hypersensitivity to 
      abacavir in some, but not all, populations.
PG  - 203-11
AB  - Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. 
      Approximately 5% of patients treated with abacavir develop a hypersensitivity 
      reaction that requires discontinuation of the drug. In an initial pharmacogenetic 
      study conducted in a predominantly White male population, multiple markers in the 
      human leukocyte antigen (HLA)-B chromosomal region were associated with 
      hypersensitivity to abacavir. The HLA-B*5701 association has now been confirmed 
      in White males in a subsequent, larger study (n=293, p=4.7 x 10(-18)) and is also 
      observed in White females (n=56, p=6.8 x 10(-6)) and Hispanics (n=104, p=2.1 x 
      10(-4)). HLA-B*5701 was not associated with hypersensitivity in Blacks (n=78, 
      p=0.27). HLA-B*5701 alone lacks sufficient predictive value to identify patients 
      at risk for hypersensitivity to abacavir across diverse patient populations. 
      Efforts are ongoing to identify markers with sufficient sensitivity and 
      specificity to be clinically useful. Even after a marker set is identified, 
      appropriate clinical identification and management of hypersensitivity to 
      abacavir must remain the cornerstone of clinical practice.
FAU - Hughes, Arlene R
AU  - Hughes AR
AD  - GlaxoSmithKline, NC 27709, USA. arh48207@gsk.com
FAU - Mosteller, Michael
AU  - Mosteller M
FAU - Bansal, Aruna T
AU  - Bansal AT
FAU - Davies, Kirstie
AU  - Davies K
FAU - Haneline, Stephen A
AU  - Haneline SA
FAU - Lai, Eric H
AU  - Lai EH
FAU - Nangle, Keith
AU  - Nangle K
FAU - Scott, Trevor
AU  - Scott T
FAU - Spreen, William R
AU  - Spreen WR
FAU - Warren, Liling L
AU  - Warren LL
FAU - Roses, Allen D
AU  - Roses AD
CN  - CNA30027 Study Team
CN  - CNA30032 Study Team
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-B Antigens)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Anti-HIV Agents/*adverse effects
MH  - Black People/genetics
MH  - Case-Control Studies
MH  - Dideoxynucleosides/*adverse effects
MH  - Drug Hypersensitivity/*etiology/metabolism
MH  - Female
MH  - Genetic Markers
MH  - *Genetic Variation
MH  - Genotype
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Male
MH  - Polymorphism, Single Nucleotide
MH  - Retrospective Studies
MH  - Tumor Necrosis Factor-alpha/genetics
MH  - White People/genetics
EDAT- 2004/03/16 05:00
MHDA- 2004/08/07 05:00
CRDT- 2004/03/16 05:00
PHST- 2004/03/16 05:00 [pubmed]
PHST- 2004/08/07 05:00 [medline]
PHST- 2004/03/16 05:00 [entrez]
AID - 10.1517/phgs.5.2.203.27481 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2004 Mar;5(2):203-11. doi: 10.1517/phgs.5.2.203.27481.